Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug could stop absence seizures without extra meds

NCT ID NCT04666610

Completed Disease control Sponsor: UCB Biopharma SRL Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 24, 2026 · Updated 3 times

Summary

This study tests whether brivaracetam, taken as an oral solution, can stop absence seizures in people aged 2 to 25 with childhood or juvenile absence epilepsy. Participants receive either the drug or a placebo, and seizure freedom is checked using a 24-hour EEG after 14 days. The goal is to see if brivaracetam alone can control seizures safely.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
brivaracetam (oral solution)
What this could lead to
If successful, brivaracetam could become a new first-line treatment option for children and young adults with absence epilepsy, potentially reducing or stopping seizures without needing other drugs.
What could go wrong
This is a Phase 3 trial, but it is still experimental. The drug may not prove more effective than placebo, and side effects or lack of long-term seizure control are possible. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHILDHOOD ABSENCE EPILEPSY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

childhood absence epilepsy epilepsy Epilepsy, Absence juvenile absence epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHILDHOOD ABSENCE EPILEPSY JUVENILE ABSENCE EPILEPSY

Contacts and locations

Locations

  • N01269 100

    New Brunswick, New Jersey, 08901, United States

  • N01269 101

    Tampa, Florida, 33612, United States

  • N01269 104

    Winter Park, Florida, 32789, United States

  • N01269 105

    Orange, California, 92868-3874, United States

  • N01269 106

    Philadelphia, Pennsylvania, 19134, United States

  • N01269 109

    Winston-Salem, North Carolina, 27109, United States

  • N01269 110

    Augusta, Georgia, 30912, United States

  • N01269 111

    Miami, Florida, 33155-3009, United States

  • N01269 115

    Birmingham, Alabama, 35233, United States

  • N01269 116

    Denver, Colorado, 80202, United States

  • N01269 320

    Pavia, Italy

  • N01269 321

    Milan, Italy

  • N01269 322

    Roma, Italy

  • N01269 323

    Messina, Italy

  • N01269 324

    Milan, Italy

  • N01269 325

    Roma, Italy

  • N01269 326

    Verona, Italy

  • N01269 354

    Terrassa, Spain

  • N01269 400

    Tbilisi, Georgia

  • N01269 401

    Tbilisi, Georgia

  • N01269 402

    Tbilisi, Georgia

  • N01269 403

    Tbilisi, Georgia

  • N01269 405

    Tbilisi, Georgia

  • N01269 560

    Iași, Romania

  • N01269 561

    Timişoara, Judeţ Timiş, Romania

  • N01269 562

    Bucharest, Romania

  • N01269 563

    Bucharest, Romania

  • N01269 600

    Dnipro, Ukraine

  • N01269 601

    Dnipro, Ukraine

  • N01269 602

    Vinnytsia, Ukraine

  • N01269 604

    Kharkiv, Ukraine

  • N01269 607

    Uzhhorod, Ukraine

  • N01269 630

    Dubnica nad Váhom, Slovakia

  • N01269 631

    Nové Zámky, Slovakia

  • N01269 632

    Bardejov, Slovakia

More trials for these conditions

Other studies related to the condition(s) this trial covers.